Figure 1.

Lapatinib induces AnxA6 expression in TNBC cells. (A) AnxA6 mRNA levels from a microarray analysis of tissues from TBCRC001 clinical trial of stage IV TNBC patients before (pre) and after (post) treatment with cetuximab with or without carboplatin. *AnxA6 expression in pretreatment versus post-treatment tissues (P = 0.039). (B–E) Representative blots of the effects of lapatinib on the expression of AnxA6. The indicated cell lines were treated with 1 µM lapatinib for up to 5 days (B), the indicated concentrations of gefitinib, canertinib and erlotinib (C) or the cytotoxic drugs paclitaxel (D) or carboplatin (E). Equal amounts of whole-cell extracts were analyzed by western blotting using antibodies against AnxA6 and GAPDH as the loading control. The relative intensity of the protein bands was analyzed using the NIH Image J software and quantified relative to control mock-treated cells.